血清中低密度脂蛋白胆固醇(low density lipoprotein cholesterol, LDL-C)浓度与冠心病的发生密切相关,而LDL-C主要是通过肝细胞表面的LDL受体(LDL receptor,LDLR)清除。前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin kexin type 9, PCSK9)可结合肝细胞表面LDLR并与其共同内吞入内体,介导LDLR进入溶酶体使其降解,从而参与血胆固醇的调节,在维持脂代谢稳态中发挥重要作用。目前对PCSK9的研究已取得一定的进展,但其发挥作用的确切机制还不是很清楚,在本文中作者就PCSK9在脂代谢调节中的作用以及其发挥作用的分子机制作一综述。

[1] TIBOLLA G,NORATA G D,ARTALI R,et al.Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutrition, metabolism, and cardiovascular diseases[J].NMCD,2011,21:835-843.
[2] STEINBERG D,WITZTUM J L.Inhibition of PCSK9:a powerful weapon for achieving ideal LDL cholesterol levels[J].P Natl Acad Sci USA,2009,106:9546-9547.
[3] 张正生,冯毅,刘乃丰.髓性过氧化物酶与动脉粥样硬化相关性研究进展[J].现代医学,2003,31(2),136-138.
[4] CONSTANTINIDES A,KAPPELLE P J,LAMBERT G,et al. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9[J].Arch Med Res,2012,43:11-14.
[5] SEIDAH N G.PCSK9 as a therapeutic target of dyslipidemia[J].Expert Opin Ther Targets,2009,13:19-28.
[6] COHEN J C,BOERWINKLE E,MOSLEY T H Jr,et al.Sequence variations in PCSK9, low LDL, and protection against coronary heart disease[J].N Engl J Med,2006,354:1264-1272.
[7] NAURECKIENCE S,MA L,SREEKUMAR K,et al.Functional characterization of Narc 1, a novel proteinase related to proteinase K[J].Arch Biochem Biophys,2003,420:55-67.
[8] BENJANNET S,RHAINS D,ESSALMANI R,et al.NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol[J].J Biol Chem,2004,279:48865-48875.
[9] McNUTT M C,LAGACE T A,HORTON J D.Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells[J].J Biol Chem,2007,282:20799-20803.
[10] GREFHOST A,McNUTT M C,LAGACE T A,et al.Plasma PCSK9 preferentially reduces liver LDL receptors in mice[J].J Lipid Res,2008,49:1303-1311.
[11] LAMBERT G,CHARLTON F,RYE K A,et al.Molecular basis of PCSK9 function[J].Atherosclerosis,2009,203:1-7.
[12] ZHANG D W,LAGACE T A,GARUTI R,et al.Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation[J].J Biol Chem,2007,282:18602-18612.
[13] FISHER T S,LO-SURDO P,PANDIT S,et al.Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation[J].J Biol Chem,2007,282:20502-20512.
[14] BROWN M S,GOLDSTEIN J L.A receptor-mediated pathway for cholesterol homeostasis[J].Science,1986,232:34-47.
[15] LAGACE T A,CURTIS D E,GARUTI R,et al.Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice[J].J Clin Invest, 2006,116:2995-3005.
[16] LI J,TUMANUT C,GAVIGAN J A,et al.Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity[J].Biochem J,2007,406:203-207.
[17] SCHMIDT R J,BEYER T P,BENSCH W R,et al.Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo[J].Biochem Biophys Res Commun,2008,370:634-640.
[18] PARK S W, MOON Y A, HORTON J D.Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver[J].J Biol Chem,2004,279:50630-50638.
[19] CHEN Y,WANG H,YU L,et al.Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor degradation[J].Biochem Biophys Res Commun,2011,415:515-518.
[20] FERRI N,TIBOLLA G,PIRILLO A,et al.Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels[J]. Atherosclerosis,2012,220:381-386.
[21] LIU M,WU G,BAYSAROWICH J,et al.PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain[J].J Lipid Res, 2010,51:2611-5618.
[22] LUO Y,WARREN L,XIA D,et al.Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice[J].J Lipid Res,2009,50:1581-1588.
[23] MAYER G,POIRIER S,SEIDAH N G.Annexin A2 is a Cterminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels[J].J Biol Chem,2008,283:31791-31801.
[24] POIRIER S, MAYER G, BENJANNET S, et al.The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2[J].J Biol Chem,2008,283:2363-2372.
[25] LI H,LIU J.The novel function of HINFP as a coactivator in sterol-regulated transcription of PCSK9 in HepG2 cells[J]. Biochem J,2012,443:757-768.
[26] LI H,DONG B,PARK S W,et al.Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine[J].J Biol Chem,2009,284:28885-28895.
[27] ABIFADEL M,VARRET M,RABES J P,et al.Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J].Nat Genet,2003,34:154-156.
[28] SHIOJI K,MANNAMI T,KOKUBO Y,et al.Genetic variants in PCSK9 affect the cholesterol level in Japanese[J].J Hum Genet,2004,49:109-114.
[29] TIMMS K M,WAGNER S,SAMUELS M E,et al.A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree[J].Human Genet,2004,114:349-353.
[30] LEREN T P.Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia[J]. Clin Genet,2004,65:419-422.
[31] KHERA A.Statins, plasma proprotein convertase subtilisin/kexin type 9 concentrations, and LDL lowering[J].Clin Chem,2012,58:6-7.
[32] HUIJGEN R,FOUCHIER S W,DENOUN M,et al.Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia[J].J Lipid Res,2012,53:979-983.
[33] WU C Y,TANG Z H,JIANG L,et al.PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway[J].Mol Cell Biochem,2012,359:347-358.
[34] UMANS-ECKENHAUSENMA,DEFSCHEJC,SIJBRANDS E J, et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands[J].Lancet,2001,357:165-168.
[35] LAKOSKI S G,LAGACE T A,COHEN J C,et al.Genetic and metabolic determinants of plasma PCSK9 levels[J].J Clin Endocrinol Metab,2009,94:2537-2543.
[36] NIESEN M,BEDI M,LOPEZ D.Diabetes alters LDL receptor and PCSK9 expression in rat liver[J].Arch Biochem Biophys,2008,470:111-115.
[37] MBIKAY M,SIROIRS F,MAYNE J,et al.PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities[J].FEBS Letters,2010,584:701-906.
[38] LANGHI C,LE MAY C,GMYR V,et al.PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion[J].Biochem Biophys Res Commun,2009,390:1288-1293.
[39] CARIOU B,LE MAY C,COSTET P.Clinical aspects of PCSK9[J].Atherosclerosis,2011,216:258-265.
[40] MIYAZAWA H, HONDA T, MIYAUCHI S,et al.Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration[J].Clin Chim Acta,2012,413:154-159.
[41] GRAHAM M J,LEMONIDIS K M,WHIPPLE C P,et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice[J].J Lipid Res, 2007,48:763-767.
[42] 江凌,李卫,姜涛,等.糖尿病患者的颈动脉内-中膜厚度与血脂关系的探讨[J].现代医学,2003,31(6):412-413.